A forum for researchers, students and applicants in the field of cyclodextrin technology
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
In May, 2020, CycloLab announced a collaboration, where University of California, Berkeley, Excivion and CycloLab teamed-up to evaluate the antiviral
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, announced that it has entered into an exclusive worldwide license agreement with
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
CycloLab celebrates birthday of L. Szente (70), former CEO Lajos Szente has been contributing to the development of the global
The amelioration of postprandial glucose and insulin responses to bread is of great importance since it may have significant beneficial
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,
Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
